Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer
Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer
Not yet recruiting · NCT06528483 · Registry updated 2024-07-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, bladder transitional cell carcinoma, neoplasm, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Not yet recruiting | Phase 2 | 2024-07-30 | NCT06528483 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 62 |
| Gilead Sciences | 180 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fondazione IRCCS Istituto Nazionale dei Tumori di Milano | Milan | Italy | 5 |